Ottimo Pharma
How LOTTE Biologics Plans to Become a Top-Ten Global Biomanufacturing CDMO
LOTTE Biologics did not exist four years ago. Today it is operating a 40,000-litre biomanufacturing campus in New York, running a dedicated antibody-drug conjugate facility, breaking ground on a $3.3 billion manufacturing campus in South Korea, and expanding its second antibody manufacturing agreement with a clinical-stage biotech targeting dual-paratopic cancer immunotherapy. The pace is intentional.…
